Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study. - Holtzman NG; Im A; Curtis LM; Schulz E; Sharma R; Pirsl F; Berman A; Ostojic A; Magone MT; Cowen EW; Mays JW; Comis LE; et al. (Blood advances, 2026)